No Data
Chongqing Pharscin Pharmaceutical (002907.SZ) plans to have two products selected in the tenth round of national pharmaceutical centralized procurement.
Chongqing Pharscin Pharmaceutical (002907.SZ) issued an announcement that on December 12, 2024, the company participated in the national organization...
Chongqing Pharscin Pharmaceutical (002907.SZ): The compound polyethylene glycol electrolyte powder (III) and the metasulfone leca tablet are proposed to be selected for centralized procurement.
On December 13, Gelonghui reported that Chongqing Pharscin Pharmaceutical (002907.SZ) participated in the 10th batch of national centralized pharmaceutical procurement organized by the National Organization of Pharmaceutical Joint Procurement Office on December 12, 2024. According to the "Proposed Selection Results for National Centralized Pharmaceutical Procurement" (GYYD2024-2) issued by the Joint Procurement Office, the company's products, Compound Polyethylene Glycol Electrolyte Powder (Ⅲ) and Mesylate Rasagiline Tablets, are proposed for selection in this centralized procurement.
Chongqing Pharscin Pharmaceutical (SZSE:002907) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Five Years, but the Stock Rallies 7.0% This Past Week
Chongqing Pharscin Pharmaceutical (002907.SZ): Received the approval notice for the supplemental application of the pharmaceutical for Fumaric Acid Voronlase Tablets.
On December 10, Gelonghui reported that Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company recently received the approval notice for the supplemental application of its product, fumaric acid vonoprazan tablets (10mg and 20mg) (hereinafter referred to as "the pharmaceutical"), issued by the National Medical Products Administration (hereinafter referred to as "the National Medical Products Administration"). The notice needed to change the indications and dosage information in the product insert of fumaric acid vonoprazan tablets (10mg and 20mg). The indications were revised from "reflux esophagitis" to "
Chongqing pharscin pharmaceutical (002907.SZ): Agomelatine tablets received the pharmaceutical registration certificate.
On December 3, Guolonghui reported that chongqing pharscin pharmaceutical (002907.SZ) announced that the company recently received the "Drug Registration Certificate" (Certificate No: 2024S02963) approved and issued by the National Medical Products Administration for its product Agomelatine Tablets (hereinafter referred to as "the pharmaceutical"). According to data from Yaobang Network, the overall market share of Agomelatine Tablets in 2023 was 0.924 billion yuan. This pharmaceutical is a new type of antidepressant, and its mechanism of action breaks through the traditional monoamine neurotransmitter system by activating melatonin receptors (MT1 and MT2) and antagonizing 5-HT2C receptors, exerting an antidepressant effect.
Pharscin Pharmaceutical Gets Nod to Market Agomelatine
Chongqing Pharscin Pharmaceutical (SZSE:002907) Sheds CN¥372m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Year
